GHRP
CJC-1295 (No DAC)/Ipamorelin Blend 5+5mg
Summary Description: The CJC-1295 (no DAC) + Ipamorelin peptide blend merges two potent growth hormone secretagogues to synergistically enhance physiologic GH pulsatility. This research-only combination stimulates both GHRH and ghrelin receptor pathways, yielding amplified and sustained GH release while maintaining endocrine feedback sensitivity.
Products will arrive in a lyophilized (powder) form for maximum stability
Hexarelin 5mg
Summary Description: Hexarelin is a synthetic hexapeptide classified as a growth hormone secretagogue (GHS). It acts as a potent agonist of the ghrelin receptor (GHS-R1a), promoting robust stimulation of endogenous growth hormone (GH) release. Unlike endogenous GHRH, Hexarelin has a distinct structure and dual-site activity, acting at both the hypothalamus and pituitary. Beyond GH secretion, Hexarelin exhibits cardiotropic effects, including improved cardiac output, and has been shown to counteract bone loss in preclinical models. Its enhanced stability and resistance to enzymatic degradation make it a preferred research tool for investigating GH-related physiology and GH-independent mechanisms1.
Products will arrive in a lyophilized (powder) form for maximum stability
Ipamorelin 5mg
Summary Description: Ipamorelin is a synthetic pentapeptide and selective agonist of the growth hormone secretagogue receptor (GHS-R1a), developed to stimulate natural growth hormone (GH) secretion while minimizing off-target effects. Unlike earlier GH secretagogues, ipamorelin exhibits high selectivity, minimal activity at other hormonal axes (ACTH, cortisol, or prolactin), and potent GH release in both animals and humans.
Products will arrive in a lyophilized (powder) form for maximum stability
Sermorelin 10mg
Summary Description: Sermorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH), designed to stimulate endogenous growth hormone (GH) secretion through physiologic activation of the hypothalamic-pituitary axis. Structurally identical to the biologically active 1β29 N-terminal amino acids of native GHRH, Sermorelin preserves full receptor agonist activity. It was previously approved by the FDA for diagnostic evaluation and treatment of pediatric GH deficiency and is now widely used off-label in research and clinical settings to address adult-onset GH insufficiency and age-related hormonal decline.
Products will arrive in a lyophilized (powder) form for maximum stability
Tesamorelin 10mg
Summary Description: Tesamorelin is a synthetic peptide analogue of growth hormone-releasing hormone (GHRH), developed for the reduction of excess abdominal fat in HIV-associated lipodystrophy. It stimulates endogenous growth hormone (GH) secretion, thereby increasing insulin-like growth factor-1 (IGF-1) levels and promoting lipolysis. Tesamorelin selectively reduces visceral adipose tissue (VAT) without significant effects on subcutaneous fat and improves body image parameters. Its stability-enhancing N-terminal modification allows for effective subcutaneous administration, and it is FDA-approved for HIV-related lipodystrophy.
Products will arrive in a lyophilized (powder) form for maximum stability
Tesamorelin 20mg
Summary Description: Tesamorelin is a synthetic peptide analogue of growth hormone-releasing hormone (GHRH), developed for the reduction of excess abdominal fat in HIV-associated lipodystrophy. It stimulates endogenous growth hormone (GH) secretion, thereby increasing insulin-like growth factor-1 (IGF-1) levels and promoting lipolysis. Tesamorelin selectively reduces visceral adipose tissue (VAT) without significant effects on subcutaneous fat and improves body image parameters. Its stability-enhancing N-terminal modification allows for effective subcutaneous administration, and it is FDA-approved for HIV-related lipodystrophy.